These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38782182)

  • 61. Metabolomic Phenotype of Hepatic Steatosis and Fibrosis in Mexican Children Living with Obesity.
    Garibay-Nieto N; Pedraza-Escudero K; Omaña-Guzmán I; Garcés-Hernández MJ; Villanueva-Ortega E; Flores-Torres M; Pérez-Hernández JL; León-Hernández M; Laresgoiti-Servitje E; Palacios-González B; López-Alvarenga JC; Lisker-Melman M; Vadillo-Ortega F
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893503
    [No Abstract]   [Full Text] [Related]  

  • 62. Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.
    Mak AL; Wassenaar N; van Dijk AM; Troelstra M; Houttu V; van Son K; Driessen S; Zwirs D; van den Berg-Faay S; Shumbayawonda E; Runge J; Doukas M; Verheij J; Beuers U; Nieuwdorp M; Cahen DL; Nederveen A; Gurney-Champion O; Holleboom A
    JHEP Rep; 2024 Mar; 6(3):100998. PubMed ID: 38379586
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom.
    Kuchay MS; Isaacs S; Misra A
    Diabetes Metab Syndr; 2024 May; 18(5):103034. PubMed ID: 38714040
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial.
    Mogna-Peláez P; Riezu-Boj JI; Milagro FI; Herrero JI; Elorz M; Benito-Boillos A; Tobaruela-Resola AL; Tur JA; Martínez JA; Abete I; Zulet MA
    Clin Nutr; 2024 Jul; 43(7):1770-1781. PubMed ID: 38861890
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Role and therapeutic perspectives of extracellular vesicles derived from liver and adipose tissue in metabolic dysfunction-associated steatotic liver disease.
    Li W; Yu L
    Artif Cells Nanomed Biotechnol; 2024 Dec; 52(1):355-369. PubMed ID: 38833340
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of Wild-Type and High-risk PNPLA3 variants in a Human Biomimetic Liver Microphysiology System for Metabolic Dysfunction-associated Steatotic Liver Disease Precision Therapy.
    Xia M; Varmazyad M; Palacin IP; Gavlock DC; Debiasio R; LaRocca G; Reese C; Florentino R; Faccioli LAP; Brown JA; Vernetti LA; Schurdak ME; Stern AM; Gough A; Behari J; Soto-Gutierrez A; Taylor DL; Miedel M
    bioRxiv; 2024 May; ():. PubMed ID: 38712213
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Nendouvhada LP; Sibuyi NRS; Fadaka AO; Meyer S; Madiehe AM; Meyer M; Gabuza KB
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891759
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment.
    Cariou B
    Diabetes Obes Metab; 2022 Feb; 24 Suppl 2():15-27. PubMed ID: 35014161
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study.
    Martínez-Montoro JI; Martínez-Sánchez MA; Balaguer-Román A; Fernández-Ruiz VE; Hernández-Barceló JE; Ferrer-Gómez M; Frutos MD; Núñez-Sánchez MÁ; Fernández-García JC; Ramos-Molina B
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732557
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association between Metabolic-Dysfunction-Associated Steatotic Liver Disease and Hepatic Cancer: Current Concepts and Future Challenges.
    Bader H; Yamin S; Alshahwan H; Farraj H; Maghnam J; Abu Omar Y
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892843
    [No Abstract]   [Full Text] [Related]  

  • 75. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Altered lipid metabolism as a predisposing factor for liver metastasis in MASLD.
    Kim SJ; Hyun J
    Mol Cells; 2024 Feb; 47(2):100010. PubMed ID: 38237744
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents.
    Maldonado-Rojas ADC; Zuarth-Vázquez JM; Uribe M; Barbero-Becerra VJ
    Ann Hepatol; 2024; 29(2):101182. PubMed ID: 38042482
    [TBL] [Abstract][Full Text] [Related]  

  • 78. MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists.
    Cooreman MP; Vonghia L; Francque SM
    Diabetes Res Clin Pract; 2024 Jun; 212():111688. PubMed ID: 38697298
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies.
    Kokkorakis M; Muzurović E; Volčanšek Š; Chakhtoura M; Hill MA; Mikhailidis DP; Mantzoros CS
    Pharmacol Rev; 2024 May; 76(3):454-499. PubMed ID: 38697855
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Zazueta A; Valenzuela-Pérez L; Ortiz-López N; Pinto-León A; Torres V; Guiñez D; Aliaga N; Merino P; Sandoval A; Covarrubias N; Pérez de Arce E; Cattaneo M; Urzúa A; Roblero JP; Poniachik J; Gotteland M; Magne F; Beltrán CJ
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.